 Dacarbazine
"Dacarbazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
| Descriptor ID |
D003606
|
| MeSH Number(s) |
D02.925.200 D03.383.129.308.240
|
| Concept/Terms |
Dacarbazine- Dacarbazine
- Dimethyl Imidazole Carboxamide
- Carboxamide, Dimethyl Imidazole
- Imidazole Carboxamide, Dimethyl
- DTIC
- ICDT
- Decarbazine
- 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
- DIC
- Dimethyl Triazeno Imidazole Carboxamide
|
Below are MeSH descriptors whose meaning is more general than "Dacarbazine".
Below are MeSH descriptors whose meaning is more specific than "Dacarbazine".
This graph shows the total number of publications written about "Dacarbazine" by people in this website by year, and whether "Dacarbazine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1995 | 0 | 2 | 2 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 2 | 2 | | 2007 | 1 | 0 | 1 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 1 | 2 | | 2012 | 1 | 3 | 4 | | 2013 | 1 | 3 | 4 | | 2014 | 1 | 4 | 5 | | 2015 | 4 | 2 | 6 | | 2016 | 1 | 5 | 6 | | 2017 | 0 | 3 | 3 | | 2018 | 1 | 1 | 2 | | 2020 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dacarbazine" by people in Profiles.
-
Germano IM, Ziu M, Wen P, Ormond DR, Olson JJ. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. J Neurooncol. 2022 Jun; 158(2):225-253.
-
Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open. 2020 09 01; 3(9):e2013935.
-
Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dr?no B. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib???cobimetinib: a pooled analysis of four clinical trials. J Transl Med. 2020 08 03; 18(1):294.
-
Hauschild A, Larkin J, Ribas A, Dr?no B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. JAMA Oncol. 2018 10 01; 4(10):1382-1388.
-
Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018 09 01; 29(9):1995-2002.
-
Pinnix CC, Wirth A, Milgrom SA, Andraos TY, Aristophanous M, Pham M, Hancock D, Ludmir EB, Gunther JR, Fanale MA, Oki Y, Nastoupil L, Chuang HH, Mikhaeel NG, Dabaja BS. Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. Leuk Lymphoma. 2018 11; 59(11):2650-2659.
-
Milgrom SA, Pinnix CC, Gunther JR, Fanale M, Dabaja BS. Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee. Br J Haematol. 2019 01; 184(2):292-293.
-
Milgrom SA, Pinnix CC, Chuang H, Oki Y, Akhtari M, Mawlawi O, Garg N, Gunther JR, Reddy JP, Smith GL, Rohren E, Hagemeister FB, Lee HJ, Fayad LE, Dong W, Osborne EM, Abou Yehia Z, Fanale M, Dabaja BS. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? Br J Haematol. 2017 11; 179(3):488-496.
-
Rusthoven CG, Koshy M, Sher DJ. Radiation plus Temozolomide in Patients with Glioblastoma. N Engl J Med. 2017 06 01; 376(22):2195-2197.
-
Fishbein L, Ben-Maimon S, Keefe S, Cengel K, Pryma DA, Loaiza-Bonilla A, Fraker DL, Nathanson KL, Cohen DL. SDHB mutation carriers with malignant pheochromocytoma respond better to CVD. Endocr Relat Cancer. 2017 08; 24(8):L51-L55.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|